TipRanks on MSN

Felix Group Holdings Announces CEO Transition as Company Prepares for Next Growth Phase

Felix Group Holdings Ltd. ( ($AU:FLX) ) just unveiled an announcement. Felix Group Holdings Ltd announced the resignation of its Co-Founder and ...
Business Insider

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces ...
Nasdaq

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

Session Title: Gene therapy and cellular immunotherapy - ClinicalPresentation ID: S262Session date and time: Saturday, June 10, 2023, 11:00 – 11:15 EDT, 16:00 ...
Seeking Alpha

Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL

LONDON, May 22, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics (AUTL) plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it ...
KLFY News 10

Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO

76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysis Potential best in class ...
WGHP

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent ...
ksn.com

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

A conference call and webcast to discuss the presented data will be held at 9:30 am EDT/2:30 pm BST on Saturday June 1, 2024. Conference call participants should pre-register using this link to ...